FDA grants Breakthrough Therapy Designation status for acalabrutinib
It has been announced that the FDA has awarded AstraZeneca’s…
It has been announced that the FDA has awarded AstraZeneca’s acalabrutinib product for MCL treatment Breakthrough Therapy Designation...